
Human Specific Research Conference
The Centre for Human Specific Research welcomes you to our first conference, set in the heart of Newcastle.
From Idea to Impact: Advancing Human-Specific Research as a Community
A new era in biomedical research is taking shape as the scientific community increasingly shifts towards research centred on human cells, human tissue, and human data. At the forefront of this shift are the scientists and groups actively pursuing the development and adoption of more effective, ethical, and human-relevant approaches.
The Human Specific Research Conference will convene this growing interdisciplinary community to foster knowledge exchange, collaboration, and innovation across all areas of human-focused research.

21-22 April 2027 | Crowne Plaza Newcastle
View the Programme
Our 2-day programme is constantly being added to – here’s your most up-to-date version:
Please note: The programme is subject to change.
Call for Abstracts
We are pleased to invite submissions for the Human Specific Research Conference, which will bring together participants at all career stages to share expertise, showcase emerging technologies, and highlight advances driving the transition towards more human-relevant research and testing approaches.
Our plenary sessions will focus on Building Complexity, Bridging Academia and Industry, Integrating In Silico and In Vitro Approaches, and Building Community to Overcome Barriers.
We welcome applications for abstracts (max 400 words) from all stages of your career. These will be presented as one of either:
- Oral presentation
- Poster presentation
Abstracts on any human-specific research topic will be considered. This includes, but is not limited to:
- Human-focused technologies and approaches (e.g., 2D and 3D cellular models, microphysiological systems, tissue slices and explants, omics technologies, and in silico approaches)
- Non-animal derived product (e.g., biomaterials, media supplements, and affinity reagents)
- Research Resources
- Regulation and Policy
- Education, Training, and Career Development.
Abstract Submission Deadline: Sunday 20 December 2026
Plenary Sessions
All plenary sessions will be made up of 3x 20 minute presentations and a 30 minute panel discussion.
Day 1 – Morning Plenary: Building Complexity
This session brings together researchers who have advanced their models in complexity (e.g., from 2D to 3D, or from 3D to MPS), sharing the thinking behind these transitions, the pathways they followed, and the challenges they addressed along the way.
Chair:
Dr Dania Movia
Dr Dania Movia is an Assistant Professor in Biomedical & Health Sciences in the Department of Biology at Maynooth University and a Principal Investigator at the Kathleen Lonsdale Institute for Human Health Research (Republic of Ireland). In 2023, she founded the Humane Biomedical Research Lab, Ireland’s first wet laboratory dedicated entirely to animal-free respiratory research and a member of the Alliance for Human Relevant Science. Her research focuses on advancing human-relevant models to accelerate the translation of preclinical findings into effective treatments for respiratory diseases without animal experimentation. Recognised for her leadership in animal-free science, she was included in the Irish Hospital Professional News Top 100 (2021), received the Animal-Free Research UK Outstanding Scientist Award (2025), and was runner-up for the Replacing Animal Research ChangeMaker Award (2026).

Speakers:
Professor John Greenman: From Biopsy to Patient-Specific Treatment: 20 Years of Tumour-on-Chip Innovation at Hull
John is a tumour immunologist who has morphed into someone who spends most of his time developing lab-on-a-chip technology for personalised medicine against solid tumours. His interdisciplinary Biomicrofluidics group in Hull, comprising clinicians, chemists and engineers, has been pioneering the development and adoption of bespoke microfluidic devices for almost 20 years. The group designs and fabricate devices from a range of materials depending on the desired end-use, with a move to using 3D printed devices in biocompatible polymers as this facilitates faster scale-up. The group has extensive experience of maintaining different tumour types, these include: glioblastoma, head and neck squamous cell carcinoma, thyroid, renal and colorectal tissue.
Professor Greenman’s abstract:
Work at the University of Hull in the microfluidic field started in 2005 with the stated challenge of keeping biopsies of tumour tissue alive, and to develop technology that could predict patient outcome and allow more precise treatment. Work commenced using glass-etched devices with epoxy-resin fittings and tubing; these were very unreliable devices. However, the tissue-on-chip idea was strongly supported by clinicians who could immediately see the benefits of the approach if the tissue on chip responses were fully representative of the patients. Therefore, this has been the underpinning rationale of the Hull lab’s work. The resulting devices have come about through strong collaborations between biologists, chemists, oncologists, surgeons, and bioengineers.
A network of surgical collaborators has provided: glioblastoma (GBM), a range of head & neck malignancies, ovarian, kidney and colorectal cancer. The tissue has either been studied as 12-18mg pieces, approximately 2 mm3, or vibratome-sliced 400-450 µm thick sections perfused on two unique devices. It was important to maximise the information which could be gained thus projects focussed on both the tissue, accepting this is an end-point assay, and the effluent that bathed the tissue as this can be sampled over the time-period tissue is maintained on chip.
Histopathologists have provided essential support throughout with an early question being asked, “Can you diagnose tumour based on tissue maintained on chip” after various time points; the answer for all tumour types analysed to date has been “yes”. As expected, there are differences in maintenance time between tumours, e.g. squamous cell carcinoma of the head and neck remain function for 4-7 days, whereas GBM have been maintained in a viable state for up to 21 days, as well as heterogeneity between patients with the same tumour type.
More recently there has been a major focus on making robust, easy to use devices, whilst simultaneously manufacturing to scale and reducing waste. Our latest device (approximately 7 x 6cm), now in iteration 5, is CNC machine-cut or 3D printed in biocompatible resin and either can be used almost indefinitely. These devices can hold a range of disposable 2 x 1cm inserts that accommodate small pieces of tissue, tissue slices, spheroids, or cell monolayers. The advantage of having a standard device means the flow parameters are well understood, and this has been optimised for high-resolution microscopy or, in a different model, for use in Category 3 or 4 containment.

Dr Cátia Neto
Cátia is a Lecturer in Pharmaceutical and Health Technologies at Cardiff University, working at the interface of neuroscience, cancer biology, and immunology. She develops patient-derived, human-specific models, including induced pluripotent stem cell (iPSC)-based systems, to investigate glioblastoma biology and tumour-immune interactions. Her work combines advanced 3D in vitro models with live-cell imaging and high-content analysis to capture dynamic cell-cell interactions and communication in human disease. By advancing physiologically relevant human model systems, her research aims to improve translational drug discovery and reduce reliance on animal models, with broader applications in brain tumours, neuro-inflammatory diseases, and kidney disease.

Professor Valerie Speirs: From 2D monolayers to physiological complexity: Advancing human-specific in vitro cell culture
Chair of our Scientific Advisory Panel, Val is also Chair in Molecular Oncology at the University of Aberdeen having relocated in 2018 after many years at the University of Leeds. She is one of the founders of the Breast Cancer Now Tissue Bank which collects and makes breast cancer tissue samples available for researchers across the UK and beyond. She uses these in her own work to develop better in vitro models of breast cancer to understand breast cancer biology. She co-directs the Aberdeen Cancer Centre, bringing together a team of scientists and clinicians working collaboratively to deliver patient-centred research, which aims to translate new laboratory findings into the clinic with the goal of directly improving patient outcomes.
Professor Speirs’s abstract:
Traditional two-dimensional (2D) monolayer cell culture systems have been the cornerstone of biomedical research for decades. However, their inability to replicate complex microenvironmental architectures, biochemical gradients, mechanical cues and heterotypic cell-cell interactions limits their clinical translation. Moving beyond 2D models requires a systematic transition toward complex three-dimensional (3D) in vitro systems that capture human tissue biology with greater physiological fidelity.
This talk will showcase practical approaches that my lab has taken to develop human-specific 3D tissue models, drawing on our experience transitioning beyond traditional 2D cell culture. Topics will include scaffold-free spheroids, biomaterial-based platforms and organ-on-a-chip systems incorporating primary human fibroblasts and endothelial networks. By recreating key aspects of the tissue microenvironment, these models restore cellular organisation and function, reveal clinically relevant drug responses, and better capture disease-associated extracellular matrix dynamics than conventional monolayer cultures.
This presentation will provide a practical roadmap for researchers seeking to implement human-relevant, animal-free models. By adopting advanced 3D tissue systems, researchers can better replicate human disease biology, helping to bridge the translational gap between preclinical studies and clinical outcomes while supporting the development of more predictive and ethically responsible therapeutics.

Day 1 – Afternoon Plenary: Bridging Academia and Industry
This session examines how academia and industry can collaborate to advance human-specific research, outlining the key requirements and priorities of each, and exploring practical routes to strengthen engagement.
Co-Chairs:
Professor Mirela Delibegovic
Prof Mirela Delibegovic, FRSE, is the Regius Chair of Physiology and the Director of Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen.
Prof Delibegovic’s academic research for the past 25+ years has focused on the causes and consequences of development of diabetes and complications associated with diabetes. She works closely with industry, SMEs and the NHS, and work developed through these collaborations was recently highlighted by the United Nations Academic Impact publication as the example of a successful collaboration between academia and industry. Prof Delibegovic sits on several national and international funding and scientific advisory boards and is passionate about career development of staff and students, public engagement in research, academia/industry collaborations and knowledge exchange.

Dr Catherine Headley
Catherine is Chief Executive Officer of the University of Manchester Innovation Factory, Manchester’s subsidiary company responsible for spinout creation, IP licensing and investment. She has many years of experience of working at the interface between academia and the commercial world, building partnerships and programmes across that interface. Catherine has led several initiatives in the knowledge exchange sphere, and is passionate about the impact that can be generated through partnerships and research commercialisation. Catherine previously worked in the pharmaceutical industry, leading programmes to develop novel technologies for API manufacture. Her research background is in organic chemistry.

Speakers:
Professor Nicholas Barnes
Professor Barnes is a translational pharmacologist and has been a member of the University of Birmingham Medical School Faculty since 1990. He is also a founder member of the Neurotrauma Research Group within the NIHR Surgical Reconstruction and Microbiology Research Centre at the Queen Elizabeth Hospital, Birmingham, one of the largest referral hospitals in Europe. His research spans from human cellular and molecular pharmacological mechanisms to assessing drug efficacy in clinical trial and has generated an extensive list of over 150 research papers. Professor Barnes is Chairman of the International Union of Basic and Clinical Pharmacology Nomenclature Committee for Serotonin Receptors, a Councilor of the International Society for Serotonin Research and a Fellow of the British Pharmacological Society.

Professor Lorna Harries: Translating biology without using animals: challenges and opportunities
Lorna is Professor of Molecular Genetics at the University of Exeter College of Medicine and Health. She leads the RNA-mediated disease mechanisms group, and is a Co-Founder, director and Chief Scientific Officer for SENISCA, a senotherapeutics spin out company built on research form the Harries team. Lorna has interests in omics approaches to the study of human ageing and age-related disease processes in man, and her work ranges from ‘big data’ analyses to detailed individual molecular analysis of particular genes.
Professor Harries’s abstract:
The end goal of academic research is to make a real tractable difference to the world. Much academic research never makes it out of academia, with benefits to endpoint stakeholders (patients, clinicians and funders) often intangible and unclear. For those attempting to move academic research out of the laboratory and into an industry or biotech setting, the advantages, but also the challenges are clear. Currently of around 5,000 new potential drugs, only 250 will make it into trials, and of those, only 10-14% will achieve regulatory approval. Approximately 50% of new drugs advance from animal testing to trials, but 95% of these will fail because of a lack of effectiveness or safety concerns. There are compelling reasons why adopting a human-first approach will result in better translation of research findings to clinic, in terms of better efficacy and superior prediction of adverse effects, but this also imposes some unique challenges.
In this presentation, I will describe how we are moving research born in my academic lab towards translation and describe some of the hurdles and challenges we have faced as it moves towards the clinic. Humans are the best test subjects for human medicine, but current contract research approaches, drug regulatory guidelines and funding constraints remain issues to be debated and solved. Once we manage to overcome these, we will see better outcomes for patients, better treatment options for clinicians and a more rapid pace of translation for new medicines.

Day 2 – Morning Plenary: Integrating In silico and In Vitro Approaches
This session brings together both communities to discuss how in silico and in vitro approaches can be integrated and used in a complementary way.
Co-Chairs:
Dr Stefaan Verbruggen
Dr. Verbruggen’s research focuses on the mechanobiology of bone cells and the development of predictive in vitro and in silico models of cancer metastasis. He completed his PhD in bone cell mechanobiology at the University of Galway, followed by postdoctoral research on how fetal movements affect joint development at Imperial College London. He was then awarded a Marie Skłodowska-Curie Research Fellowship at Queen Mary University of London and, through a collaboration with Columbia University, investigated how cancer cells metastasize to bone. His lab recently received an ERC Consolidator Grant to develop organ-on-a-chip models advancing this work.

Dr Liam Weaver
Liam is an Assistant Professor of Biomedical Engineering at the University of Warwick. His research uses mechanistic and data-driven modelling approaches to investigate the multi-organ implications of treatments provided to critically ill patients. During his PhD, he developed digital twins to study the impact of non-invasive respiratory support, improving clinical understanding by quantifying treatment effects which could not be observed at the bedside. Liam currently holds a consulting role on the Digital Twins Systems Pilot, hosted by the University of Galway as part of the EU-funded STEP4NAMs project.

Speakers:
Dr Ana-Maria Cujba
Ana-Maria Cujba is a senior postdoctoral fellow in Professor Sarah Teichmann’s laboratory at the Cambridge Stem Cell Institute, University of Cambridge, supported by the Novo Nordisk NovoSTAR Fellowship. Her research combines bioinformatics, single-cell genomics, and spatial transcriptomics to study vascular and immune systems and their interface in cardiovascular disease. Within the Human Cell Atlas, she has contributed to large-scale, single-cell characterisation of vascular populations across human tissues and blood immune cells. She aims to further leverage these atlases to improve the physiological relevance of in-vitro disease models. She previously completed a PhD at King’s College London investigating monogenic diabetes using stem cells and pancreatic organoids.

Professor Alejandro Frangi: Virtual Patients, Credible Evidence: In Silico Trials and the Human-Specific Turn
Alejandro Frangi is the Bicentenary Turing Chair in Computational Medicine at the University of Manchester and Executive Director of the UK Centre of Excellence on In Silico Regulatory Science and Innovation (UK CEiRSI). He pioneers virtual patients, digital twins and in silico trials — computer-based methods that test medical devices and treatments on human-derived models rather than animals. A Fellow of the Royal Academy of Engineering and the IEEE, he advises regulators worldwide on accepting simulation as credible evidence. He co-founded the MedTech spin-outs adsilico and Oculomex Health, translating human-specific computational science into clinical practice.
Professor Frangi’s abstract:
Every source of medical evidence – bench, animal, clinical – is a model. They differ not in how “real” they are, but in their assumptions and failure modes. In silico trials make this explicit: they test devices and therapies on populations of virtual patients built from human anatomy, physiology, and data. Because they are human by construction, they do not carry the species-translation gap that limits animal studies. This talk introduces in silico methods and shows how they integrate with in vitro approaches – organ-on-chip and tissue models – into a coherent, human-specific evidence stack. It explains why this matters now: the UK, US and EU are each publishing roadmaps away from mandatory animal testing, opening the door to simulation as credible evidence. The question is no longer whether computational evidence belongs, but how we validate it well enough to trust it.

Day 2 – Afternoon Plenary: Building Community to Overcome Barriers
This session considers how community-building and collaborative initiatives can support and accelerate the development and implementation of human-specific research.
We are delighted to announce that this session is sponsored by Qkine, our Headline Sponsor.
Chair:
Professor Chris Denning
Chris Denning is Professor of Stem Cell Biology and Director of the Biodiscovery Institute (BDI). The £100m Institute is the largest research facility at the University of Nottingham and houses 850 researchers, clinicians and support staff. Research is across 6 themes of global importance, encompassing Cancer, Engineering Biology, Pioneering Therapeutics, Regenerating & Modelling Tissues, Taming Microbes, and Demystifying Biomolecular Complexity.
Spanning several of BDI’s themes, Chris’ interests are in cardiovascular differentiation of human induced pluripotent stem cells (hiPSCs) for use in drug screening and in production of new in vitro models of genetic-based cardiovascular disease. Broadly, the main areas are: 1) Disease mechanisms; 2) Gene-drug-phenotype relationships; 3) Public outreach.

Speakers:
Dr Adrian Biddle: A multi-pronged approach to cancer research: bridging the divide between the lab and the clinic
Adrian is Reader in Cancer Biology at Queen Mary University of London (QMUL), having spent 10 years building a research group following his award of an Animal Free Research UK lectureship in 2016. At QMUL, Adrian directs the Barts Centre for Squamous Cancer and is a member of the Centre for Predictive in vitro Models. His research interest is in cancer stem cells and how they are responsible for tumour metastasis and therapeutic resistance in oral cancer. He is particularly interested in how human cancers can be modelled using a combination of in vitro experimental systems and human tissue analysis.
Dr Biddle’s abstract:
How do we improve cancer outcomes for patients, whilst moving away from the use of animals? We have been developing a multi-pronged approach to cancer research combining human pathology, primary tissue models, and advanced cell culture models. By ensuring accurate in vitro modelling of human tumour biology, this approach presents an exciting opportunity for greater rapidity and success in producing clinically-relevant science. However, it is not without difficulties; ensuring rational design of experimental models, developing productive clinical collaborations, and interfacing with human tissue regulations and gatekeepers are a few of the challenges. In this talk, I will discuss our efforts to build a human-focussed experimental approach to cancer research and what we have learned along the way.

Professor Matthew Dalby: Training and Technologies for Non-Animal Models
Following a PhD at Queen Mary University of London on osteoblast responses to bioactive composites, Professor Dalby moved to Glasgow to study cell-nanoscale interactions. Awarded a BBSRC David Phillips Fellowship in 2003, he later became Professor of Cell Engineering at the University of Glasgow. Matthew is co-Director of the Centre for the Cellular Microenvironment and leads major EPSRC initiatives, including StemNiche and the MAINSTREAM Hub. His research spans stem cell engineering, nanovibrational technologies, and translational work, including veterinary trials and emerging clinical applications. Prof Dalby also directs the EPSRC-SFI lifETIME CDT. His current focus is stem cell ageing and human-relevant models for blood cancer.
Professor Dalby’s abstract:
To build a UK sector in development of human cell containing 3D models of healthy and diseased tissues to drive research, we require both training and technology development. Cohort training in the area across biology, engineering and biophysics can create a community of like-minded researchers committed to developing better science. Initiatives like the lifETIME Centre for Doctoral Training, funded by EPSRC, SFI and AFRUK, focusses on providing multidisciplinary scientific and entrepreneurial that is industry facing for PhD students. Initiatives like the EPSRC MAINSTREAM Hub for stem cell manufacturing also offer this high-value training to post-doctoral researchers.
As human cell containing models are developed, we will need new materials that mimic body tissues; innovations in synthetic hydrogels can help with this. We will also need to find ways to look into the models non-invasively and in real time so we can look at e.g. response of the models to drug treatments. Innovations in Raman and Brillouin microscopy can help to deliver this. I will discuss these training programmes and these technologies with a primary focus on models of blood cancer.

Breakout Sessions
We will also be running a number of breakout sessions across the 2 days, in parallel, covering key themes in human-specific research:
| Session | Title | Overview | Chairs and Speakers |
|---|---|---|---|
| Day 1 11:15-12:45 | Regulatory Issues from NHS Ethics to Commercialisation | New technology and change challenges regulators and governance structures; non-animal approaches are no exception. The session will have 3 presentations looking at many aspects of the process from local research NHS ethics to international commercialisation. It is important to understand these structures, and that they are continually evolving. Following the presentations there will be a significant period of time for questions and discussion. | Chair: Professor John Greenman Speaker: Dr Michael Phelan |
| Day 1 14:15-15:15 | Biobanking | TBC | Chair: Professor Valerie Speirs Speaker: Dr Kathryn Pennel |
| Day 1 14:15-15:45 | Human Blood Brain Barrier Modelling: Where Are We Now? | This panel discussion session focuses on the use of various blood-brain barrier models including 3D human multicellular, on-a-chip, and organoid models. The panel will discuss their merits and deficiencies when used in different pathologies as well as in pre-clinical testing for drug delivery, cancer metastasis and generic biomedical experiments. | Chair: Professor Geoff Pilkington Panellists: Dr Giulia Massaro, Dr Adjanie Patabendige, Dr David Dickens |
| Day 2 11:00-12:30 | Addressing the Challenges in Adopting Human-Specific, Animal-Free Science: Today’s Initiatives and Resources Hosted by Qkine, our Headline Sponsor | Despite growing momentum for human-specific research, significant barriers continue to hinder the adoption of human-focused approaches and the move away from animal-derived products. This session will examine these barriers and highlight recent initiatives and resources designed to help the research community overcome them and accelerate the shift towards fully human-specific, animal-free research. | Co-Chairs: Dr Liz Stewart, Dr Ross Dobie Speaker: Dr Fiona Saunders |
| Day 2 14:00-15:30 | Transitioning to Animal-Free Recombinant Antibodies and Mimetics | Recombinant antibodies and mimetics offer scientifically robust and more ethical alternatives to traditional monoclonal and polyclonal antibodies, yet barriers remain to their widespread adoption. This session will examine the current landscape, share first-hand experiences of transitioning to animal-free approaches, and highlight emerging resources designed to support researchers in making the transition. | Chair: TBC Speakers: Dr Alison Gray, Dr Sal Jones, Dr Ross Dobie |
Breakout Sessions: Meet your Chairs, Speakers and Panellists
Professor John Greenman
John is a tumour immunologist who has morphed into someone who spends most of his time developing lab-on-a-chip technology for personalised medicine against solid tumours. His interdisciplinary Biomicrofluidics group in Hull, comprising clinicians, chemists and engineers, has been pioneering the development and adoption of bespoke microfluidic devices for almost 20 years. The group designs and fabricate devices from a range of materials depending on the desired end-use, with a move to using 3D printed devices in biocompatible polymers as this facilitates faster scale-up. The group has extensive experience of maintaining different tumour types, these include: glioblastoma, head and neck squamous cell carcinoma, thyroid, renal and colorectal tissue.

Dr Sal Jones
Dr Sal Jones is a research technician at the University of Nottingham Biodiscovery Institute, with extensive experience in animal-free research. Since 2017 Sal has worked on human-relevant disease research models to replace and reduce animal usage, beginning with their PhD optimising a synthetic peptide hydrogel to replace mice for passaging patient-derived xenografts, and later working with human iPSCs in a xeno-free foreign body response model. In 2026 they joined the Ashworth group, culturing primary patient breast organoids in xeno-free models to entirely remove animals and animal components from the process, while developing new animal-free endpoint assays to characterise model success.

Dr Owen Kavanagh
Dr Owen Kavanagh is a Senior Lecturer in Biomedical Science at York St John University. He is a founding member of the Coalition to Illuminate and Address Animal Methods Bias (COLAAB). Animal Methods Bias is when research is unfairly evaluated because it does not include animal-based experiments and it is barrier to adoption of nonanimal research. In this talk he will provide an update on the COLAAB strategies for addressing animal methods bias in scientific publishing and funding.

Dr Giulia Massaro
Dr Massaro is a Lecturer in Gene Therapy Viral Vector Technologies at UCL School of Pharmacy, where she led the first UCL vector manufactory facility. Her research focuses on developing gene therapies for rare neurological disorders and improving viral vector design. She is developing humanised brain-on-chip models to investigate neurological disease and evaluate novel gene delivery vectors in human-based systems, supporting alternatives to animal experimentation. Dr Massaro serves on the Board of Directors of the British Society for Cell and Gene Therapy, the Association of Italian Scientists in the UK, and is a Scientific Advisor to the Humane Research Trust.

Dr Lisa Mohamet
In 2017, Lisa joined GSK preclinical R&D as a Scientific Leader to head up the advanced cellular model platform group to support lead drug discovery programs. In 2018, her team moved to help establish the Functional Genomics department. Currently, she serves as Head of Translational Cell Models within Target Discovery and leads The Stem Cell & Complex In Vitro Models Centre for Excellence at GSK. She leads a team of ~40 scientists, focussing on the application of iPSC-derived cell types & complex human in vitro systems incl. organ on a chip & organoids for use in CRISPR screening for target identification/validation & preclinical research across GSK priority therapeutic areas. She recently joined the board of ELRIG & chairs the Innovation Group.
Prior to joining GSK, Lisa was a Royal Society of Edinburgh/BBSRC Entrepreneur Fellow at The University of Manchester & co-founded StrataStem Ltd, an innovative spin-out biotech company, utilizing stem cell technology to identify stratification opportunities for Alzheimer’s disease where she continues to serve as a director.

Dr Adjanie Patabendige
Dr Adjanie Patabendige is an Associate Professor at the University of Derby specialising in the development of advanced in vitro blood-brain barrier models. Her research focuses on advancing our understanding of the mechanisms underlying blood-brain barrier dysfunction and disrupted brain fluid regulation in neurological diseases. She develops innovative human-relevant models that enable more accurate investigation of disease pathophysiology and the evaluation of potential therapeutic interventions. Her work contributes to the development of more predictive and translational approaches to neurovascular disease research. Dr Patabendige is a Scientific Adviser for Replacing Animal Research, a member of the CVB 2027 organising committee, and is committed to accelerating the transition to animal-free science through policy engagement, stakeholder collaboration, and the training of future researchers.

Dr Kathryn Pennel
Kathryn Pennel is a postdoctoral research associate from Professor Joanne Edwards laboratory in the School of Cancer Sciences, University of Glasgow. Her research focuses on the development of recapitulative ex vivo models of cancer with an interest in inflammatory signalling. Kathryn is based within Glasgow Translational Tissue Services unit, and her work mainly involves generation of primary colon, rectal and ovarian cancer models. The aim of her work is to develop better models to test novel and repurposed therapeutic agents and identify biomarkers to predict treatment response.

Dr Michael Phelan
Dr Michael Phelan is the founder and principal consultant of InnovApproach Consulting. He helps technology developers and drug sponsors validate, qualify and use New Approach Methodologies (NAMs) across global regulatory frameworks. He led the first technology accepted into the FDA’s ISTAND program for novel drug development tools and serves as an External Program Consultant to the NIH Complement-ARIE program. In Australia, he contributed to the Bellberry/ASCEPT NAMs HREC Review Checklist. He has been an invited expert speaker at international NAMs events, including a European Parliament roundtable. Previously, he grew and commercialised cell-based drug development services in the US.

Professor Valerie Speirs
Chair of our Scientific Advisory Panel, Val is also Chair in Molecular Oncology at the University of Aberdeen having relocated in 2018 after many years at the University of Leeds. She is one of the founders of the Breast Cancer Now Tissue Bank which collects and makes breast cancer tissue samples available for researchers across the UK and beyond. She uses these in her own work to develop better in vitro models of breast cancer to understand breast cancer biology. She co-directs the Aberdeen Cancer Centre, bringing together a team of scientists and clinicians working collaboratively to deliver patient-centred research, which aims to translate new laboratory findings into the clinic with the goal of directly improving patient outcomes.

Dr Melissa van Velthoven
Dr. Melissa van Velthoven is a project leader at the 3Rs Centre Utrecht (3RCU), Utrecht University. With a background in biomedical sciences and tissue engineering, she obtained her PhD from Radboud University, focusing on synthetic hydrogels for tissue regeneration. At 3RCU, she works to advance the replacement of animal-derived products in biomedical research. She coordinates initiatives including the FCS-free and BME-free Databases and the international ReALiSe working group. Her work focuses on raising awareness of ‘invisible animal use’ and supporting researchers in overcoming practical barriers to implementing animal-free alternatives.

We’re proud to be supported by our incredible Sponsors
Meet our Headline Sponsor
We’re delighted to announce Qkine as our headline sponsor!
Qkine manufactures high-purity, animal origin-free growth factors, cytokines, and other complex bioactive proteins for life science applications, including stem cell and organoid culture. Qkine addresses fundamental biological, quality, and scale-up challenges by integrating proprietary recombinant protein production processes with protein engineering approaches, delivering more reliable tools for research and bio-manufacturing. Actively supporting and innovating in emerging fields such as 3D stem cell models, organoids, cellular agriculture, cell therapy, regenerative medicine and organ-on-a-chip, Qkine aims to accelerate the impact of these technologies on human health and wellbeing.



About the Crowne Plaza Newcastle

Get to know the venue…
Crowne Plaza Newcastle is set in the heart of Newcastle in the city’s Stephenson Quarter. An IHG hotel, it boasts a modern, sophisticated event space including comfortable seating and refreshment stations along with a dedicated breakout space.
With easy transportation links and adjacent to Newcastle Central Station, this venue couldn’t be more suitable for our Human Specific Research Conference 2027.
